

Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: OC01617K		APPLICATION NO.: 10/654,546	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Timothy J. Guzi et al.		FILING DATE: 09/03/2003	
(Use several sheets if necessary)				GROUP:		1624	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
✓	AA US 5,571,813	11/05/1996	Röhler et al.				
✓	AB US 5,602,136	02/11/1997	Röhler et al.				
✓	AC US 5,602,137	02/11/1997	Röhler et al.				
✓	AD US 5,688,949	11/18/1997	Inoue et al.				
✓	AE US 5,707,997	01/13/1998	Shoji et al.				
✓	AF US 5,919,815	07/06/1999	Bradley et al.				
✓	AG US 6,040,321	03/21/2000	Kim et al.				
✓	AH US 6,191,131	02/20/2001	He et al.				
✓	AI US 6,262,096	07/17/2001	Kim et al.				
✓	AJ US 6,413,974	07/02/2002	Dumont et al.				
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
✓	AK EP 0 628 559	04/03/2002	Europe				
✓	AL EP 1 334 973	08/13/2003	Europe				
✓	AM WO 02/40485	05/23/2002	PCT				
✓	AN WO 02/50079	06/27/2002	PCT				
✓	AO WO 95/35298	12/28/1995	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
✓	AP	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224: 771-786.					
✓	AQ	Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", <i>Journal of Medical Chemistry</i> , Page EST:22.3, A-W.					
✓	AR	Metley et al., "Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects", <i>J. Med. Chem.</i> (2003), 46(2): 222-236.					
✓	AS	Novinson et al., "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5- α]pyrimidines", <i>J. Med. Chem.</i> (1977), 20(2): 286-299.					
✓	AT	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16(9): 2986-2999.					
✓	AU	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243:527-536.					
✓	AV	Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57: 3375-3380.					
✓	AW	Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5- α]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), 47(7): 928-938.					
✓	AX	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5- α]pyrimidines.", <i>Chem. Pharm. Bull</i> (1962), 10: 620-626.					
EXAMINER <i>John M. Steyer</i>				DATE CONSIDERED <i>6/17/05</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01617K	APPLICATION NO.: 10/654,546
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Timothy J. Guzl et al.	
(Use several sheets if necessary)				FILING DATE: 09/03/2003	GROUP:

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
<i>JA</i>	AA 6,107,305	08/22/2000	Misra et al.			
<i>JA</i>	AB 6,413,974 B1	07/02/2002	Dumont et al.			
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS						
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
<i>JA</i>	DE 102 23 917 A1	12/11/2003			YES	NO
<i>JA</i>	AL EP 0 628 559 A	12/14/1994				
<i>JA</i>	AM WO 02/50079 A1	06/27/2002				
<i>JA</i>	AN WO 03/091256 A1	11/06/2003				
	AO					
	AP					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
<i>JA</i>	AQ Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62)
	AR
	AS
	AT
	AU
	AV

EXAMINER <i>Jon McG...</i>	DATE CONSIDERED <i>6/17/05</i>
-------------------------------	-----------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.